Targeted genomic analysis of Mullerian adenosarcoma

被引:73
作者
Howitt, Brooke E. [1 ,2 ]
Sholl, Lynette M. [2 ,3 ,4 ]
Cin, Dal P. [2 ,4 ]
Jia, Yonghui [2 ,3 ]
Yuan, Liping [1 ,2 ]
MacConaill, Laura [2 ,3 ]
Lindeman, Neal [2 ,3 ,4 ]
Kuo, Frank [2 ,3 ,4 ]
Garcia, Elizabeth [2 ,3 ]
Nucci, Marisa R. [1 ,2 ]
Quade, Bradley J. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Womens & Perinatal Pathol Div, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Brigham & Womens Hosp, Ctr Adv Mol Diagnost, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
关键词
Mullerian; adenosarcoma; sarcomagenesis; MDM2; HMGA2; MYBL1; PANCREATIC NEUROENDOCRINE TUMORS; EPIDERMAL-GROWTH-FACTOR; DNA-SEQUENCING DATA; ENDOMETRIAL POLYP; UTERINE ADENOSARCOMA; CLINICOPATHOLOGICAL ANALYSIS; GENITAL-TRACT; HMGI-C; EXPRESSION; UTERUS;
D O I
10.1002/path.4442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mullerian adenosarcoma (MA) is a rare mixed mesenchymal tumour of the female genital tract, composed of malignant stroma and benign-appearing epithelium. Sarcomatous overgrowth (SO) is the only established histological variable associated with higher stage and shorter survival. Specific molecular or immunohistochemistry (IHC) tools for the diagnosis of MA are lacking. Our goal was to study genomic mutations and copy number variations (CNVs) in MA to understand better its pathobiology, and develop specific diagnostic and prognostic tools. DNA was extracted from 20 samples of MA from 18 subjects (12 without SO and 6 with SO), including two in which areas of both typical MA histology and SO were independently tested. Samples were analysed using a targeted next-generation sequencing assay interrogating exonic sequences of 275 cancer genes for mutations and CNVs as well as 91 introns across 30 genes for cancer-associated rearrangements. The mean number of mutations in MA with SO (mean 9.7; range 3-14) did not differ significantly from that in MA without SO (mean 9.6; range 5-16). MA with SO had significantly higher mean numbers of gene-level CNVs (24.6) compared to MA without SO (5; p = 0.0002). The most frequent amplification involved MDM2 and CDK4 (5/18; 28%), accompanied by focal CDK4 and MDM2 and diffuse HMGA2 expression using immunohistochemistry. MYBL1 amplification was seen in 4/18 (22%), predominantly in SO. Alterations in PIK3CA/AKT/PTEN pathway members were seen in 13/18 (72%). Notably, TP53 mutations were uncommon, present in only two cases with SO. Three out of 18 (17%) had mutations in ATRX, all associated with SO. No chromosomal rearrangements were identified. We have identified a number of recurrent genomic alterations in MA, including some associated with SO. Although further investigation of these findings is needed, confirmation of one or more may lead to new mechanistic insights and novel markers for this often difficult-to-diagnose tumour. Copyright (c) 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd
引用
收藏
页码:37 / 49
页数:13
相关论文
共 62 条
[1]   Diagnostic Immunohistochemistry in Uterine Sarcomas: A Study of 397 Cases [J].
Abeler, Vera M. ;
Nenodovic, Maja .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2011, 30 (03) :236-243
[2]   Immunohistochemical expression of CD10 antigen in uterine adenosarcoma [J].
Amant, F ;
Steenkiste, E ;
Schurmans, K ;
Verbist, L ;
Abeler, VM ;
Tulunay, G ;
De Jonge, E ;
Massuger, L ;
Moerman, P ;
Vergote, I .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2004, 14 (06) :1118-1121
[3]   Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma [J].
Amant, F ;
Schurmans, K ;
Steenkiste, E ;
Verbist, L ;
Abeler, VM ;
Tulunay, G ;
de Jonge, E ;
Massuger, L ;
Moerman, P ;
Vergote, I .
GYNECOLOGIC ONCOLOGY, 2004, 93 (03) :680-685
[4]   p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas [J].
Anderson, SE ;
Nonaka, D ;
Chuai, S ;
Olshen, AB ;
Chi, D ;
Sabbatini, P ;
Soslow, RA .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) :849-853
[5]   MALIGNANT MIXED MULLERIAN TUMORS OF THE UTERUS - AN IMMUNOHISTOCHEMICAL STUDY [J].
AUERBACH, HE ;
LIVOLSI, VA ;
MERINO, MJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1988, 7 (02) :123-130
[6]   Uterine adenosarcomas: A dual-institution update on staging, prognosis and survival [J].
Bernard, Brandon ;
Clarke, Blaise A. ;
Malowany, Janet I. ;
McAlpine, Jessica ;
Lee, Cheng-Han ;
Atenafu, Eshetu G. ;
Ferguson, Sarah ;
Mackay, Helen .
GYNECOLOGIC ONCOLOGY, 2013, 131 (03) :634-639
[7]  
Blom R, 1999, INT J GYNECOL CANCER, V9, P37
[8]   An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12 [J].
Bol, S ;
Wanschura, S ;
Thode, B ;
Deichert, U ;
VandeVen, WJM ;
Bartnitzke, S ;
Bullerdiek, J .
CANCER GENETICS AND CYTOGENETICS, 1996, 90 (01) :88-90
[9]   High mobility group A2 potentiates genotoxic stress in part through he modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation [J].
Boo, LN ;
Lin, HH ;
Chung, V ;
Zhou, BS ;
Louie, SG ;
O'Reilly, MA ;
Yen, Y ;
Ann, DK .
CANCER RESEARCH, 2005, 65 (15) :6622-6630
[10]   Molecular cytogenetic characterization of a case of Mullerian adenosarcoma [J].
Chen, Z ;
Hong, B ;
Drozd-Borysiuk, E ;
Coffin, C ;
Albritton, K .
CANCER GENETICS AND CYTOGENETICS, 2004, 148 (02) :129-132